ANDA Review Time Cuts Possible Without User Fees, Barr Rep Says
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Generic Drugs could reduce ANDA review times by adding 50 full time equivalents, Barr Laboratories CEO Bruce Downey told the House Energy & Commerce/Health Subcommittee June 13.
You may also be interested in...
FDA Forced OTC Switch Process Ambiguities Revealed At Subcmte. Hearing
FDA does not have an established procedure in place to prevent the disclosure of protected trade secrets in the event of a forced Rx-to-OTC switch, Center for Drug Evaluation & Research Director Janet Woodcock, MD, told a House panel June 13.
NAPM/GPhA Merger Likely Ends Generic User Fees Push In 107th
The merger agreement between the National Association of Pharmaceutical Manufacturers and the Generic Pharmaceutical Association likely means generic drug user fees will not be a focal point of the PDUFA reauthorization process.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC